Business Context and Reporting Period
The provided filing is Landec Corporation’s Form 10-Q, not a filing for Lifecore Biomedical, Inc. It covers the fiscal quarter and nine months ended February 26, 2012, compared with February 27, 2011. Landec operates through Food Products Technology, Food Export, HA-based Biomaterials (Lifecore), and Technology Licensing businesses.
Key Financial Metrics
| Metric | Three Months Ended Feb. 26, 2012 | Year-over-Year Change | Nine Months Ended Feb. 26, 2012 | Year-over-Year Change |
|---|---|---|---|---|
| Total revenue | $80.1 million | Up 9% | $234.9 million | Up 13% |
| Gross profit | $13.2 million | Up 6% | $37.4 million | Up 4% |
| Gross margin | 16.5% | Down from 17.0% | 15.9% | Down from 17.3% |
| Operating income | $4.0 million | Up 8% | $11.1 million | Down 1% |
| Net income attributable to common stockholders | $4.8 million | Up 107% | $9.9 million | Up 49% |
| Diluted earnings per share | $0.18 | Up from $0.09 | $0.38 | Up from $0.25 |
| Operating cash flow | Not separately provided | — | $8.5 million | Down from $12.4 million |
Third-quarter net margin was approximately 6.0%; nine-month net margin was approximately 4.2%. Cash and cash equivalents were $12.5 million at February 26, 2012, compared with $8.1 million at May 29, 2011. Marketable securities totaled $25.1 million, providing approximately $37.6 million of cash and marketable securities.
Total debt was $16.5 million, including $4.3 million current and $12.2 million long-term. Debt declined from $19.8 million at May 29, 2011. Lifecore’s debt is secured by its assets, guaranteed by Landec, and subject to financial covenants. A $20 million interest-rate swap effectively fixes the related borrowing rate at 4.24% through April 30, 2015.
Material Changes Versus the Prior Comparable Period
- Apio value-added revenue increased 18% in the quarter and 14% year to date, driven primarily by higher unit volumes, expanded product offerings, and additional distribution locations.
- Apio Food Products Technology gross profit increased 67% in the quarter and 20% year to date. The prior-year quarter was adversely affected by weather-related produce supply costs.
- HA-based Biomaterials revenue declined 9% in the quarter because of shipment timing and lower ophthalmic volumes, but increased 2% year to date. HA gross profit declined 3% in the quarter and 4% year to date.
- Technology Licensing revenue and gross profit declined 90% in the quarter and 32% year to date, primarily because the Monsanto agreement expired on December 1, 2011. Monsanto paid a $4.0 million termination fee, and Landec recognized $2.7 million of related license revenue during the nine-month period.
- Net income benefited materially from $3.6 million of third-quarter and $4.7 million of nine-month unrealized fair-value gains on the Windset investment, compared with other expense in the prior-year periods.
- The Company repurchased 917,244 shares for approximately $5.0 million during the first nine months, reducing shares outstanding to approximately 25.5 million at February 26, 2012.
- Capital expenditures were $3.9 million, primarily for Apio automation and Lifecore equipment. Net cash used in investing activities was $0.9 million versus $31.2 million in the prior-year period, which included the $15 million Windset investment.
Outlook, Risks, Contingencies, and Unusual Items
- Management stated that existing cash, marketable securities, and internally generated operating cash flow should fund operational and capital requirements for at least the next twelve months.
- Landec was obligated to pay the former Lifecore owner a $10.0 million earn-out before June 1, 2012. The liability was recorded at $10.0 million at February 26, 2012.
- Results are subject to seasonality, particularly in Apio’s Food Export business and Lifecore customer ordering patterns.
- Key risks include produce supply and weather conditions, customer concentration, product mix, regulatory requirements, research and development execution, intellectual-property protection, competitive technologies, licensing activity, and Lifecore debt covenant compliance.
- The five largest customers represented 44% of nine-month revenue; one Food Products Technology customer represented 17%.
- Windset fair value is based on Level 3 discounted-cash-flow assumptions, including projected cash flows, growth rates, and discount rates. Changes in these assumptions could materially affect reported earnings.
- At February 26, 2012, accumulated other comprehensive loss included a $202,000 net unrealized loss on the interest-rate swap.
- Management reported no material changes to previously disclosed risk factors, no legal proceedings, no debt defaults, and effective disclosure controls.
Important Facts for Investors to Verify
- Confirm the requested issuer: the source filing identifies Landec Corporation, while the request metadata identifies Lifecore Biomedical, Inc.
- Assess the sustainability of earnings excluding the Windset fair-value gain and related dividend income.
- Verify payment and funding of the $10.0 million Lifecore earn-out due before June 1, 2012.
- Evaluate the impact of the expired Monsanto agreement on recurring licensing revenue and profit.
- Review Lifecore debt covenants, scheduled principal payments, collateral, and Landec’s guarantee obligations.
- Monitor customer concentration, shipment timing, seasonality, weather exposure, and produce-cost volatility.
- Review the assumptions supporting the $20.4 million fair value reported for the Windset investment.